Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Surg Endosc ; 37(12): 9013-9029, 2023 12.
Artículo en Inglés | MEDLINE | ID: mdl-37910246

RESUMEN

BACKGROUND: New evidence has emerged since latest guidelines on the management of paraesophageal hernia, and guideline development methodology has evolved. Members of the European Association for Endoscopic Surgery have prioritized the management of paraesophageal hernia to be addressed by pertinent recommendations. OBJECTIVE: To develop evidence-informed clinical practice recommendations on paraesophageal hernias, through evidence synthesis and a structured evidence-to-decision framework by an interdisciplinary panel of stakeholders. METHODS: We performed three systematic reviews, and we summarized and appraised the certainty of the evidence using the GRADE methodology. A panel of general and upper gastrointestinal surgeons, gastroenterologists and a patient advocate discussed the evidence in the context of benefits and harms, the certainty of the evidence, acceptability, feasibility, equity, cost and use of resources, moderated by a Guidelines International Network-certified master guideline developer and chair. We developed the recommendations in a consensus meeting, followed by a modified Delphi survey. RESULTS: The panel suggests surgery over conservative management for asymptomatic/minimally symptomatic paraesophageal hernias (conditional recommendation), and recommends conservative management over surgery for asymptomatic/minimally symptomatic paraesophageal hernias in frail patients (strong recommendation). Further, the panel suggests mesh over sutures for hiatal closure in paraesophageal hernia repair, fundoplication over gastropexy in elective paraesophageal hernia repair, and gastropexy over fundoplication in patients who have cardiopulmonary instability and require emergency paraesophageal hernia repair (conditional recommendation). A strong recommendation means that the proposed course of action is appropriate for the vast majority of patients. A conditional recommendation means that most patients would opt for the proposed course of action, and joint decision-making of the surgeon and the patient is required. Accompanying evidence summaries and evidence-to-decision frameworks should be read when using the recommendations. This guideline applies to adult patients with moderate to large paraesophageal hernias type II to IV with at least 50% of the stomach herniated to the thoracic cavity. The full guideline with user-friendly decision aids is available in https://app.magicapp.org/#/guideline/j7q7Gn . CONCLUSION: An interdisciplinary panel provides recommendations on key topics on the management of paraesophageal hernias using highest methodological standards and following a transparent process. GUIDELINE REGISTRATION NUMBER: PREPARE-2023CN018.


Asunto(s)
Hernia Hiatal , Laparoscopía , Adulto , Humanos , Fundoplicación/métodos , Enfoque GRADE , Hernia Hiatal/cirugía , Hernia Hiatal/complicaciones , Laparoscopía/métodos , Estómago
3.
Am J Gastroenterol ; 110(5): 662-82; quiz 683, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25869390

RESUMEN

OBJECTIVES: Barrett's esophagus (BE) is a common premalignant lesion for which surveillance is recommended. This strategy is limited by considerable variations in clinical practice. We conducted an international, multidisciplinary, systematic search and evidence-based review of BE and provided consensus recommendations for clinical use in patients with nondysplastic, indefinite, and low-grade dysplasia (LGD). METHODS: We defined the scope, proposed statements, and searched electronic databases, yielding 20,558 publications that were screened, selected online, and formed the evidence base. We used a Delphi consensus process, with an 80% agreement threshold, using GRADE (Grading of Recommendations Assessment, Development and Evaluation) to categorize the quality of evidence and strength of recommendations. RESULTS: In total, 80% of respondents agreed with 55 of 127 statements in the final voting rounds. Population endoscopic screening is not recommended and screening should target only very high-risk cases of males aged over 60 years with chronic uncontrolled reflux. A new international definition of BE was agreed upon. For any degree of dysplasia, at least two specialist gastrointestinal (GI) pathologists are required. Risk factors for cancer include male gender, length of BE, and central obesity. Endoscopic resection should be used for visible, nodular areas. Surveillance is not recommended for <5 years of life expectancy. Management strategies for indefinite dysplasia (IND) and LGD were identified, including a de-escalation strategy for lower-risk patients and escalation to intervention with follow-up for higher-risk patients. CONCLUSIONS: In this uniquely large consensus process in gastroenterology, we made key clinical recommendations for the escalation/de-escalation of BE in clinical practice. We made strong recommendations for the prioritization of future research.


Asunto(s)
Esófago de Barrett/patología , Esófago de Barrett/terapia , Biomarcadores de Tumor/análisis , Consenso , Técnica Delphi , Neoplasias Esofágicas/patología , Esófago/patología , Lesiones Precancerosas/patología , Lesiones Precancerosas/terapia , Técnicas de Ablación , Factores de Edad , Biopsia , Metilación de ADN , Esofagoscopía , Humanos , Lesiones Precancerosas/química , Lesiones Precancerosas/genética , Factores de Riesgo , Factores Sexuales , Espera Vigilante/métodos
4.
Ann N Y Acad Sci ; 1325: 108-26, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25266020

RESUMEN

The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the animal reflux-inflammation models for Barrett's esophagus and esophageal adenocarcinoma; genomic/epigenomic analyses; eflornithine-based combinations; the molecular derangements that promote neoplastic transformation; the role of COX-2 inhibitors, proton pump inhibitors, and phase II trials in Barrett's adenocarcinoma; statins in chemoprevention and treatment of esophageal cancer; and biomarkers as potential targets in Barrett's adenocarcinoma.


Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias Esofágicas/diagnóstico , Neoplasias Esofágicas/prevención & control , Animales , Esófago de Barrett/diagnóstico , Esófago de Barrett/metabolismo , Esófago de Barrett/prevención & control , Biomarcadores de Tumor/metabolismo , Transformación Celular Neoplásica/metabolismo , Inhibidores de la Ciclooxigenasa 2/uso terapéutico , Eflornitina/uso terapéutico , Neoplasias Esofágicas/metabolismo , Reflujo Gastroesofágico/diagnóstico , Reflujo Gastroesofágico/metabolismo , Reflujo Gastroesofágico/prevención & control , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Paris , Inhibidores de la Bomba de Protones/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...